DEPO-MEDRONE WITH 40MG/ML LIDOCAINE
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
20-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
METHYLPREDNISOLONE ACETATE LIDOCAINE HYDROCHLORIDE
Available from:
Pharmacia Ireland
Dosage:
10
Pharmaceutical form:
Solution for Injection
Authorization date:
2001-01-28
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Depo-Medrone 40mg/ml with Lidocaine 10mg/ml Suspension for Injection, 2ml vial.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains Methylprednisolone Acetate 40 mg and Lidocaine Hydrochloride 10 mg.
Each vial contains 80mg Methylprednisolone Acetate and 20mg Lidocaine Hydrochloride.
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Suspension for Injection.
Sterile white aqueous suspension.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Depo-Medrone with Lidocaine is indicated in conditions requiring a glucocorticoid effect: e.g. anti-inflammatory or
anti-rheumatic. It is recommended for local use where the added anaesthetic effect would be considered advantageous.
4.2 Posology and method of administration
Depo
-Medrone with Lidocaine should not be mixed with any other preparation as flocculation of the product may
occur. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to
administration whenever suspension and container permit.
Therapy with Depo-Medrone with Lidocaine does not obviate the need for the conventional measures usually
employed. Although this method of treatment will ameliorate symptoms, it is
Read the complete document
